Yonsei Med J.  2006 Aug;47(4):519-523. 10.3349/ymj.2006.47.4.519.

Malignancies in Korean Patients with Inflammatory Myopathy

• Lee SW
• Jung SY
• Park MC
• Park YB
• Lee SK

• KMID: 1779502
• DOI: http://doi.org/10.3349/ymj.2006.47.4.519

Abstract

The aim of this study was to assess the prevalence and the common type of malignancies in Korean patients with polymyositis (PM) and dermatomyositis (DM) and to evaluate the differences of clinical and laboratory findings between patients with malignancy and those without malignancy. Forty-one Korean patients, who were diagnosed as PM or DM, were enrolled in this study. They fulfilled the Bohan and Peter's criteria for a definite diagnosis of PM and DM. Patients with PM were 25 and those with DM were 16. Eleven out of 41 patients (26.8%) had malignancies. The malignancy was diagnosed simultaneously or later in 81.8% of patients with inflammatory myopathy (IM). The breast cancer was the most common malignancy. In this study, forty three years old as a screening age for malignancy had 88.9% sensitivity and 50.2% specificity. The serum levels of creatine kinase (CK) were significantly lower in patients with malignancy than those without malignancy.

Keyword

Dermatomyositis; polymyositis; malignancy

MeSH Terms

Sensitivity and Specificity
Polymyositis/*complications/epidemiology
Neoplasms/*complications/epidemiology
Myositis/*complications/epidemiology
Middle Aged
Male
Korea
Inflammation
Humans
Female
Dermatomyositis/*complications/epidemiology
Creatine Kinase/blood
Aged
Adult

Reference

1. Chakravarty E, Genovese MC. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol. 2003. 15:35–43.

2. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001. 134:1087–1095.

3. Stertz G. Polymyositis. Berl Klin Wochenschr. 1916. 53:489.

4. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002. 28:723–741.

5. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002. 41:729–734.

6. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol. 2001. 144:825–831.

7. Chan HL. Dermatomyositis and cancer: East and West. J Am Acad Dermatol. 2000. 42:699–700.

8. Choi SJ, Lee HY, Lee MH, Kim JH. A clinical analysis of 39 patients with dermatomyositis-polymyositis. Korean J Med. 1985. 21:104–111.

9. Kim SM, Choi YH, Oh MD, Nam TS, Chung MH, Pai HJ, et al. A clinical analysis of 100 patients with dermatomyositis-polymyositis. Korean J Med. 1990. 39:812–822.

10. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975. 292:403–407.

11. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001. 357:96–100.

12. Mebazaa A, Boussen H, Nouira R, Rokbani L, Ben Osman-Dhahri A, Bouaouina N, et al. Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol. 2003. 48:530–534.

13. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995. 6:9–13.

14. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korea central cancer registry program 2000: based on registered data from 131 hospitals. Cancer Res Treat. 2002. 34:77–83.

15. Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc. 1986. 61:645–653.